Drawing for OPJEFTI

USPTO serial 88839073

OPJEFTI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
TANNER, MICHAEL R
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with OPJEFTI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly BRISTOL-MYERS SQUIBB COMPANYP.O. BOX 4000TRADEMARK DEPT., MAILSTOP D.4243PRINCETON, NJ 08648-4000

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 2, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 2, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 23, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 22, 2024EX5GSOU EXTENSION 5 GRANTED—
Jan 22, 2024AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 3, 2024EXT5SOU EXTENSION 5 FILED—
Jan 3, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 2, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 2, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 15, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 13, 2023EX4GSOU EXTENSION 4 GRANTED—
Jul 13, 2023EXT4SOU EXTENSION 4 FILED—
Jul 13, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 26, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 24, 2023EX3GSOU EXTENSION 3 GRANTED—
Jan 24, 2023EXT3SOU EXTENSION 3 FILED—
Jan 24, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 15, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 13, 2022EX2GSOU EXTENSION 2 GRANTED—
Jul 13, 2022EXT2SOU EXTENSION 2 FILED—
Jul 13, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 21, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 19, 2022EX1GSOU EXTENSION 1 GRANTED—
Jan 19, 2022EXT1SOU EXTENSION 1 FILED—
Jan 19, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 27, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 13, 2021ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Mar 3, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 2, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 2, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 13, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 30, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 5, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 4, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 4, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 4, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2020DOCKASSIGNED TO EXAMINER—
Mar 23, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 21, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance